{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.3","upperLimit":"18.1","value":"7.3"},{"comment":"The median Overall Survival and the associated 95% CI was not reached.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The upper limit of the 95% CI interval was undetermined due to the heavy censoring.","groupId":"OG002","lowerLimit":"9.5","upperLimit":"NA","value":"31.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"18"}],"units":"Participants"}],"description":"The overall survival was evaluated using the Kaplan-Meier estimator.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received Temsirolimus (CCI-779) IV over 30 minutes on days 1,8,15, and 22. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients were followed every 8 weeks. Aggressive B-cell lymphoma group was defined as patients with histologic subtypes included diffuse large B-cell lymphoma and transformed follicular lymphoma.","id":"OG000","title":"Aggressive B-cell Lymphoma"},{"description":"Patients received Temsirolimus (CCI-779) IV over 30 minutes on days 1,8,15, and 22. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients were followed every 8 weeks. Follicular lymphoma group was defined as patients with histologic subtypes included follicular lymphoma.","id":"OG001","title":"Follicular Lymphoma"},{"description":"Patients received Temsirolimus (CCI-779) IV over 30 minutes on days 1,8,15, and 22. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients were followed every 8 weeks. Chronic lymphocytic leukemia group was defined as patients with histologic subtypes included chronic lymphocytic leukemia, small lymphocytic lymphoma, and other indolent lymphomas.","id":"OG002","title":"Chronic Lymphocytic Leukemia"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 6 years","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"Month"}